Last reviewed · How we verify

VIBEGRON — Competitive Intelligence Brief

VIBEGRON (VIBEGRON) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: beta3-Adrenergic Agonist [EPC].

marketed beta3-Adrenergic Agonist [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

VIBEGRON (VIBEGRON).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
VIBEGRON TARGET VIBEGRON marketed beta3-Adrenergic Agonist [EPC] 2018-01-01
Myrbetriq MIRABEGRON Apgdi marketed beta3-Adrenergic Agonist [EPC] Beta-3 adrenergic receptor 2012-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (beta3-Adrenergic Agonist [EPC] class)

  1. · 1 drug in this class
  2. Apgdi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VIBEGRON — Competitive Intelligence Brief. https://druglandscape.com/ci/vibegron. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: